Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis

Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis

BackgroundThe EGFR gene encodes a protein that stimulates molecular pathways that allow the growth and development of the tumor microenvironment. The current preferred tyrosine kinase inhibitor (TKI) for the first-line treatment of EGFRm metastatic non-small cell lung cancer (NSCLC) is osimertinib....

Полное описание

Библиографические подробности
Главные авторы: Rodrigo Motta-Guerrero, Alejandro Leon Garrido-Lecca, Virgilio E. Failoc-Rojas, Ana Calle-Villavicencio, Robert Villacorta-Carranza, Yesenia Huerta-Collado, Alicia Torres-Mera, Mario J. Valladares-Garrido, Víctor Rivera-Francia, Carlos Carracedo, Luis Raez
Формат: Статья
Язык:English
Опубликовано: Frontiers Media S.A. 2024-01-01
Серии:Frontiers in Oncology
Предметы:
non-small cell lung cancer
EGFR gene
VEGFR
tyrosine kinase inhibitor
erlotinib
Online-ссылка:https://www.frontiersin.org/articles/10.3389/fonc.2023.1335373/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1335373/full

Схожие документы